[ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2017, Volume : 10, Issue : 9
First page : ( 3095) Last page : ( 3097)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2017.00549.2

Computational Screening of the Phytocompounds from the Plant Ballota nigra Linn against the Human Papillomavirus (HPV) E6

Marimuthu Nishandhini, Viswanathan T, Radha Mahendran*, Suganya Jeyabaskar

Department of Bioinformatics, School of Life Sciences, Vels University, Pallavaram, Chennai-600117, Tamil Nadu, India

*Corresponding Author E-mail: mahen.radha@gmail.com

Online published on 16 May, 2018.


Cancer is major cause of death rate in world wide. Cervical cancer is the second most common type of cancer in women, where the cancer develops at lower part of the uterus. Literature studies clearly depicts that the mainstream of the human cervical cancers are caused by high risk HPV infections. Human Papillomavirus (HPV) E6 protein was the most prevalent high risk oncogene causing cervical cancer and still there is no proficient drug against this disease. Many researchers are involved to combat this cancer using phytodrugs. The current research was to identify the potential plant based drug against the cervical cancer using docking studies. Docking studies of eighteen phyto compounds from the plant Ballota nigra of the family Lamiaceae were carried out using Argus Lab. From the results, Ballotinone and Ballonigrin were found to have a best binding efficiency with the active site residues of the protein. The binding energies of the 2 compounds were-12.0691 Kcal/mol and-10.2564 Kcal/mol. This study provides promising anti-cervial cancer inhibitor for further drug development.



Ballota nigra Linn, Phytocompounds, Binding energies, docking studies and Cervical cancer.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
722,642,641 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.